A
Alan T McGown
Researcher at University of Salford
Publications - 130
Citations - 5889
Alan T McGown is an academic researcher from University of Salford. The author has contributed to research in topics: Combretastatin & Combretastatin A-4. The author has an hindex of 39, co-authored 130 publications receiving 5663 citations. Previous affiliations of Alan T McGown include University of Sheffield & Cardiff University.
Papers
More filters
Journal ArticleDOI
Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle.
TL;DR: This review describes the biochemistry of tubulin, microtubules, and the mitotic spindle and describes the natural and synthetic agents which are known to interact with tubulin.
Journal ArticleDOI
Potent antimitotic and cell growth inhibitory properties of substituted chalcones
Sylvie Ducki,Richard Forrest,John A. Hadfield,Alex Kendall,Nicholas J. Lawrence,Alan T McGown,David Rennison +6 more
TL;DR: A series of substituted chalcones was synthesised and screened for cytotoxic activity against the K562 human leukaemia cell line and (E)-3-(3"-Hydroxy-4"-methoxyphenyl)-2-methyl-1-(3',4',5'- trimethoxyl)-prop-2-en-1-one [IC50 (K562) 0.21 nM] was found to be the most active.
Journal ArticleDOI
Molecular Imaging and Biological Evaluation of HuMV833 Anti-VEGF Antibody: Implications for Trial Design of Antiangiogenic Antibodies
Gordon C Jayson,Jamal Zweit,Alan Jackson,C Mulatero,Peter J Julyan,Malcolm R Ranson,Lynn Broughton,John Wagstaff,L Hakannson,Gerard Groenewegen,John Bailey,Nigel K Smith,D.L. Hastings,Jeremy A L Lawrance,Hamied A. Haroon,Timothy H Ward,Alan T McGown,Meina Tang,D. Levitt,Sandrine Marreaud,Frederic Lehmann,Manfred Herold,Heinz Zwierzina +22 more
TL;DR: Because of the heterogeneity in tumor biology with respect to antibody uptake and clearance, it is suggested that either intrapatient dose escalation approaches or larger, more precisely defined patient cohorts would be preferable to conventional strategies in the design of phase I studies with antiangiogenic compounds like HuMV833.
Journal Article
Tubulin and microtubules as targets for anticancer drugs.
TL;DR: The ability of these agents to destroy tumour vasculature is described, which represents an exciting new molecular target in the design of anticancer drugs.
Journal ArticleDOI
In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug.
TL;DR: It is concluded that combretastatin A-4 and its prodrug caused extensive necrosis in MAC 15A s.c. and orthotopic colon cancer and metastases, resulting in anti-tumour effects.